Evaluation of the potential use of adipose-derived mesenchymal stromal cells in the treatment of canine atopic dermatitis: A pilot study

Veterinary Therapeutics

Volumn 11, Issue 2, 2010, Pages

  Hall, M N ^a   Rosenkrantz, W S ^a   Hong, J H ^b   Griffin, C E ^c   Mendelsohn, C M ^a  

^a Animal Dermatology Clinic   (United States)

^b RNL Biostar Inc   (United States)

^c Animal Dermatology Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ADIPOSE TISSUE; ANIMAL; ANIMAL DISEASE; ARTICLE; ATOPIC DERMATITIS; CLINICAL TRIAL; CYTOLOGY; DOG; DOG DISEASE; FEMALE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMA CELL; PHYSIOLOGY; PILOT STUDY;

ADIPOSE TISSUE; ANIMALS; ANTI-BACTERIAL AGENTS; DERMATITIS, ATOPIC; DOG DISEASES; DOGS; FEMALE; MALE; MESENCHYMAL STEM CELL TRANSPLANTATION; MESENCHYMAL STROMAL CELLS; PILOT PROJECTS;

EID: 77956521921     PISSN: 15283593     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (77)

1. Scott DW, Miller WH, Griffin CE. Small Animal Dermatology. 6th ed. Philadelphia: WB Saunders; 2001.
2. Halliwell R. Revised nomenclature for veterinary allergy. Vet Immunol Immunopathol 2006;114:207-208.
3. Marsella R, Samuelson D, Harrington L. Immunohistochemical evaluation of filaggrin polyclonal antibody in atopic and normal beagles. Vet Dermatol 2009;20:547-554.
4. Marsella R, Samuelson D. Unraveling the skin barrier: a new paradigm for atopic dermatitis and house dust mites. Vet Dermatol 2009;20:533-540.
5. Olivry T, Mueller RS. Evidence-based veterinary dermatology: a systemic review of the pharmacotherapy of canine atopic dermatitis. Vet Dermatol 2003;14: 121-146.
6. Olivry T, DeBoer DJ, Griffin CE, et al. The ACVD task force on canine atopic dermatitis: forewords and lexicon. Vet Immunol Immunopathol 2001;81:143-146.
7. Mueller RK, Fieseler KV, Zabel S, et al. Conventional and rush immunotherapy in canine atopic dermatitis. In: Hillier A, Foster AP, Kwochka KW, eds. Advances in Veterinary Dermatology V. Oxford: Blackwell Publishing; 2005:60-69.
8. Olivry T, Sousa CA. The ACVD task force on canine atopic dermatitis (XIX): general principles of therapy. Vet Immunol Immunopathol 2001;81:311-316.
9. Olivry T, Sousa CA. The ACVD task force on canine atopic dermatitis (XX): glucocorticoid pharmacotherapy. Vet Immunol Immunopathol 2001;81:317-322.
10. Griffin CE, Hillier A. The ACVD task force on canine atopic dermatitis (XXIV): allergen-specific immunotherapy. Vet Immunol Immunopathol 2001;81: 363-383.
11. Olivry T, Rivierre C, Jackson HA, et al. Cyclosporine decreases skin lesions and pruritus in dogs with atopic dermatitis: a blinded randomized prednisolone-controlled trial. Vet Dermatol 2002;13:77-87.
12. DeBoer DJ, Griffin CE. The ACVD task force on canine atopic dermatitis (XXI): antihistamine pharmacotherapy. Vet Immunol Immunopathol 2001;81:44-48.
13. Olivry T, Marsella R, Hillier A. The ACVD task force on canine atopic dermatitis (XXIII): are essential fatty acids effective? Vet Immunol Immunopathol 2001;81: 347-362.
14. Mueller RS, Bettenay SV. Long-term immunotherapy of 146 dogs with atopic dermatitis-a retrospective study. Aust Vet Pract 1996;26:128-132.
15. Willemse A, Van der Brom WE, Rijnberk A. Effect of hyposensitisation on atopic dermatitis in dogs. JAVMA 1984;184:1277-1280.
16. Keppel KE, Campbell KL, Zuckermann FA, et al. Quantitation of canine regulatory T cell populations, serum interleukin-10 and allergen-specific IgE concentrations in healthy control dogs and canine atopic dermatitis patients receiving allergen-specific immunotherapy. Vet Immunol Immunopathol 2008;123: 337-344.
17. Marsella R. Calcineurin inhibitors: a novel approach to canine atopic dermatitis. JAAHA 2005;41(2):92-97.
18. Locke M, Windsor J, Dunbar PR. Human adiposederived stem cells: isolation, characterization and applications in surgery. A N Z J Surg 2009;79:235-244.
19. Mirmira RG. Stem cells and the future of organ transplantation. Curr Opin Organ Transplant 2010;15:52-53.
20. Mizumo H. Adipose-derived stem cells for tissue repair and regeneration: ten years of research and a literature review. J Nippon Med Sch 2009;76(2):56-66.
21. Götherström C. Immunomodulation by mutlipotent mesenchymal stromal cells. Transplantation 2007;84: S35-S37.
22. Nakagami H, Morishita R, Maeda K, et al. Adipose tissue-derived stromal cells as a novel option of regenerative cell therapy. J Atheroscler Thromb 2005;13:77-81.
23. Lui ZJ, Zhuge Y, Velazquez OC. Trafficking and differentiation of mesenchymal stem cells. J Cell Biochem 2009;106:984-991.
24. Haniffa MA, Collin MP, Buckley CD, et al. Mesenchymal stem cells: the fibroblasts' new clothes? Haematologica 2009;94(2):258-263.
25. Bunnell BA, Flaat M, Gagliardi C, et al. Adiposederived stem cells: isolation, expansion and differentiation. Methods 2008;45:115-120.
26. Sordi V. Mesenchymal stem cell homing capacity. Transplantation 2009;87:S42-S45.
27. Schäffler A, Büchler C. Concise review: adipose tissue- derived stromal cells-basic and clinical implications for novel cell-based therapies. Stem Cells 2007; 25:818-827.
28. Wan CD, Cheng R, Wang HB, et al. Immunomodulatory effects of mesenchymal stem cells derived from adipose tissues in a rat orthotopic liver transplantation model. Hepatobilary Pancreat Dis Int 2008;7:29-33.
29. McIntosh K, Zvonic S, Garrett S, et al. The immunogenicity of human adipose derived cells: temporal changes in vitro. Stem Cells 2006;24:1245-1253.
30. Mitchell JB, McIntosh K, Zvonic S, et al. The immunophenotype of human adipose derived cells: temporal changes in stromal- and stem cell-associated markers. Stem Cells 2006;24:376-385.
31. Schipper BM, Marra KG, Zhang W, et al. Regional anatomic and age effects on cell function of human adipose-derived stem cells. Ann Plast Surg 2008;60(5): 538-544.
32. Barry FP, Murphy JM. Mesenchymal stem cells: clinical applications and biological characterization. Int J Biochem Cell Biol 2004;36:568-584.
33. Caplan AI, Dennis JE. Mesenchymal stem cells as trophic modulators. J Cell Biochem 2006;98:1076-1084.
34. Ren G, Zhao X, Zhang L, et al. Inflammatory cytokine- induced intercellular adhesion molecule-1 and vascular cell adhesion molecule-1 in mesenchymal stem cells are critical for immunosuppression. J Immunol 2010;184:2321-2328.
35. Black LL, Gaynor J, Adams C, et al. Effect of intraarticular injection of autologous adipose-derived mesenchymal stem and regenerative cells on clinical signs of chronic osteoarthritis of the elbow joint in dogs. Vet Ther 2008;9(3):192-200.
36. Vet Stem Inc. Data on file. 2005-2008.
37. Sampaolesi M, Blot S, D'Antona G, et al. Mesoangioblast stem cells ameliorate muscle function in dystrophic dogs. Nature 2006;127:1304-1306.
38. Richardson LE, Dudhia J, Clegg PD, et al. Stem cells in veterinary medicine-attempts at regenerating equine tendon after injury. Trends Biotechnol 2007;25:409-416.
39. Black LL, Gaynor J, Gahring D, et al. Effects of adipose- derived mesenchymal stem and regenerative cells on lameness in dogs with chronic osteoarthritis of the coxofemoral joints: a randomized, double-blinded, multicenter, controlled trial. Vet Ther 2007;8(4):272-284.
40. Ryu HH, Lim JH, Byeon YE, et al. Functional recovery and neural differentiation after transplantation of allogenic adipose-derived stem cells in canine model of acute spinal cord injury. J Vet Sci 2009;10(4):273-284.
41. Gerdoni E, Gallo B, Casazza S, et al. Mesenchymal stem cells effectively modulate pathogenic immune response in experimental autoimmune encephalomyelitis. Ann Neurol 2007;61:219-227.
42. Uccelli A, Pistoia V, Moretta L. Mesenchymal stem cells: a new strategy for immunosuppression? Trends Immunol 2007;28(5):219-226.
43. Tasso R, Pennesi G. When stem cells meet immunoregulation. Int Immunopharmacol 2009;9:596-598.
44. Newman RE, Yoo D, LeRoux MA, et al. Treatment of inflammatory disease with mesenchymal stem cells. Inflamm Allergy Drug Targets 2009;8:110-123.
45. Siegel G, Schäfer R, Dazzi F. The immunosuppressive properties of mesenchymal stem cells. Transplantation 2009;87:S45-S49.
46. Grounds MD, Davis KE. The allure of stem cell therapy for muscular dystrophy. Neuromuscul Disord 2007;17:206-208.
47. Riordan NH, Ichim TE, Min WP, et al. Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med 2009;7:29-38.
48. Tyndall A, Uccelli A. Multipotent mesenchymal stromal cells for autoimmune disease: teaching new dogs old tricks. Bone Marrow Transplant 2009;43:821-828.
49. González MA, Gonzalez-Rey G, Rico L, et al. Treatment of experimental arthritis by inducing immune tolerance with human adipose-derived mesenchymal stem cells. Arthritis Rheumatism 2009;60(4):1006-1019.
50. Garcia-Olmo D, Garcia-Arrnaz M, Herreros D. Expanded adipose-derived stem cells for the treatment of complex perianal fistula including Crohn's disease. Exp Opin Biol Ther 2008;8(9):1417-1423.
51. Kim WS, Park BS, Sung JH. The wound-healing and antioxidant effects of adipose-derived stem cells. Exp Opin Biol Ther 2009;9(7):879-887.
52. Song B, Song Y, Lin Q, et al. Human adipose tissue-derived mesenchymal stromal cells as salvage therapy for treatment of severe refractory acute graft-vs.-host disease in two children. Pediatr Transplant 2007;11: 814-817.
53. Dazzi F, Marelli-Berg MF. Mesenchymal stem cells for graft-versus-host disease: close encounters of T cells. Eur J Immunol 2008;38:1479-1482.
54. Slavin S, Kurkalli BGS, Karussis D. The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 2008;110(9):943-946.
55. Augello A, Tasso R, Negrini SM, et al. Cell therapy using allogenic bone marrow mesenchymal stem cells prevents tissue damage in collagen-induced arthritis. Arthritis Rheumatism 2007;56(4):1175-1186.
56. Nasef A, Mathieu N, Alain C, et al. Immunosuppressive effects of mesenchymal stem cells: involvement of HLA-G. Transplantation 2007;84:231-237.
57. Marsella R, Olivry T. The ACVD task force on canine atopic dermatitis (VII): mediators of cutaneous inflammation. Vet Immunol Immunopathol 2001;81: 205-213.
58. Tarpataki N. Recent developments in canine atopic dermatitis: a review. Acta Veterinaria Hungarica 2006;54:473-484.
59. Jutel M, Akdis M, Budak F. IL-10 and TGF-beta co- operate in the regulatory T cell response to mucosal allergens in normal immunity and specific immunotherapy. Eur J Immunol 2003;33:1205-1214.
60. Prélaud P, Guaguére E, Alhaidari Z. Re-evaluation of diagnostic criteria of canine atopic dermatitis. Rev Med Vet 1998;149:1057-1064.
61. Willemse A. Atopic skin disease: a review and a reconsideration of diagnostic criteria. J Small Anim Pract 1986;27:771-778.
62. Griffin CE, DeBoer DJ. The ACVD task force on canine atopic dermatitis (XIV): clinical manifestation of canine atopic dermatitis. Vet Immunol Immunopathol 2001;81:255-269.
63. Vieria NM, Brandalise V, Zucconi E, et al. Isolation, characterization, and differentiation potential of canine adipose-derived stem cells. Cell Transplant 2010;19:279-289.
64. Torres FC, Rodrigues CJ, Stocchero IN, et al. Stem cells from the fat tissue of rabbits: an easy-to-find experimental source. Aesthetic Plast Surg 2007;31:574-578.
65. Vidal MA, Kilroy GE, Lopez MJ, et al. Characterization of equine adipose tissue-derived stromal cells: adipogenic and osteogenic capacity and comparison with bone marrow-derived mesenchymal stem cells. Vet Surg 2007;36:613-622.
66. Williams KJ, Picou AA, Kish SL, et al. Isolation and characterization of porcine adipose tissue-derived adult stem cells. Cells Tissues Organs 2008;188:251-258.
67. Yamamoto N, Akamatsu H, Hasegawa S, et al. Isolation of multipotent stem cells from mouse adipose tissue. J Dermatol Sci 2007;48:43-52.
68. Zuk PA, Zhu M, Ashijan P, et al. Human adipose tissue is a source of multipotent stem cells. Mol Biol Cell 2002;13:4279-4295.
69. Olivry T, Marsella R, Iwasaki T, et al. Validation of CADESI-03, a severity scale for clinical trials enrolling dogs with atopic dermatitis. Vet Dermatol 2007;18:78-86.
70. Olivry T, Mueller R, Nuttal T, et al. Determination of CADESI-03 thresholds for increasing severity levels of canine atopic dermatitis. Vet Dermatol 2008;19:115-119.
71. Hill PB, Lau P, Rybnicek J. Development of an owner-assessed scale to measure the severity of pruritus in dogs. Vet Dermatol 2007;18:301-308.
72. Lloyd DH. Microbial overgrowth. Proc 23rd ECVD/ESVD Annu Cong 2009:258-261.
73. Rodriguez AM, Pisani D, Dechense C, et al. Transplantation of a multipotent cell population from human adipose tissue induces dystrophin expression in the immunocompetent mdx mouse. J Exp Med 2005;201:1397-1405.
74. Madonna R, Geng YJ, De Caterina R. Adipose tissuederived stem cells-characterization and potential for cardiovascular repair. Arterioscler Thromb Vasc Biol 2009;29:1723-1729.
75. Aggarwal S, Pittenger MF. Human mesenchymal stem cells modulate allogenic immune cell responses. Blood 2005;105:1815-1822.
76. Mackenzie TC, Flake AW. Human mesenchymal stem cells persist, demonstrate site-specific multipotential differentiation, and are present in sites of wound healing and tissue regeneration after transplantation into fetal sheep. Blood Cells Mol Dis 2001;27:1-4.
77. Devine SM, Bartholomew AM, Mahmud N, et al. Mesenchymal stem cells are capable of homing to the bone marrow of non-human primates following systemic infusion. Exp Hematol 2001;29:244-255.